PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia

Article OPEN
Hoyle, M.; Pavey, T.; Ciani, O.; Crathorne, L.; Jones-Hughes, T.; Cooper, C.; Osipenko, L.; Venkatachalam, M.; Rudin, C.; Ukoumunne, O.; Garside, R.; Anderson, R.;
Share - Bookmark